SCHEMBL20399490

SCHEMBL20399490

CCS(=O)(=O)c1cccc(NC(=O)OC(C)(C)C)c1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.43
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSP90AB1 P08238 1/20 0.40
KCNQ4 P56696 3/20 0.39
KCNQ5 Q9NR82 3/20 0.39
CA1 P00915 2/20 0.39
CA12 O43570 1/20 0.39
CA7 P43166 1/20 0.39
CA14 Q9ULX7 1/20 0.39
METAP1 P53582 1/20 0.38
CNR2 P34972 1/20 0.37
BRD9 Q9H8M2 1/20 0.37
CA2 P00918 1/20 0.36
MMP13 P45452 1/20 0.36
CYP17A1 P05093 1/20 0.36
DDR1 Q08345 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28340525 0.85 CA1 (0.39) CA1CA2DDR1ALDH1A1HPGD
SCHEMBL20399181 0.81 MEN1 (0.41) CA1CA2DDR1HPGD
SCHEMBL29781362 0.79 RXFP1 (0.45) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL28856066 0.79 RXFP1 (0.47) RXFP1LMNAPOLBKCNQ4KCNQ5
SCHEMBL28697219 0.79 RXFP1 (0.47) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL11932847 0.78 LMNA (0.45) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL19912770 0.78 LMNA (0.45) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL31166733 0.78 LMNA (0.45) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL30092445 0.77 RXFP1 (0.42) RXFP1LMNAPOLBHSP90AA1HSP90AB1
SCHEMBL29909461 0.77 RXFP1 (0.46) RXFP1LMNAPOLBHSP90AA1HSP90AB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260028329-A1 JAK1 SELECTIVE INHIBITORS ASTRAZENECA AB (SE) 2026-01-29 US disclosed
US-12473272-B2 JAK1 selective inhibitors ASTRAZENECA AB (SE) 2025-11-18 US disclosed
US-20240208947-A1 JAK1 SELECTIVE INHIBITORS ASTRAZENECA AB (SE) 2024-06-27 US disclosed
EP-4219470-A1 JAK1 SELECTIVE INHIBITORS Astrazeneca AB (SE) 2023-08-02 EP disclosed
EP-3571192-B1 JAK1 SELECTIVE INHIBITORS ASTRAZENECA AB (SE) 2022-11-30 EP disclosed
WO-2018134213-A1 JAK1 SELECTIVE INHIBITORS ASTRAZENECA AB (SE) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473272-B2 JAK1 selective inhibitors JAK1, JAK2, JAK3 RXFP1 146/4885LMNA 4785/4885POLB 3967/4885
US-20260028329-A1 JAK1 SELECTIVE INHIBITORS JAK1, JAK2, JAK3 RXFP1 206/4885LMNA 4238/4885POLB 2635/4885
US-20240208947-A1 JAK1 SELECTIVE INHIBITORS JAK1, JAK2, JAK3 RXFP1 146/4885LMNA 4785/4885POLB 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.